Cardiovascular (CV) toxicity is a major cause leading to compound attrition throughout the drug discovery and development process as well as withdrawal of FDA-approved drugs from the market. Current preclinical CV toxicity testing methods fail to evaluate risk for cardiomyopathy and other forms of structural cardiotoxicity. There are few in vitro assays available to determine the potential for structural cardiotoxicity.
Our cardiotoxicity assay, Cardio quickPredictTM, indicates the cardiotoxicity potential of drug candidates and other lead compounds, based on changes in human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) metabolism and viability.
Cardio quickPredictTM provides an indication of cardiotoxicity and identifies functional or structural cardiotoxicants with a single assay. This method can be combined with other assays or endpoints for a comprehensive understanding of a compound’s cardiotoxicity liability.
Cardio quickPredictTM Process
Accurate prediction of functional and structural cardiotoxicity
Data for multiple exposure levels
Human test system
Positive and negative controls on every plate to ensure assay performance
Results using a small sample of test article (approx.15 mg)
Cardio quickPredictTM is 86% Predictive of Carditoxicity
In a recent study, we exposed iPSC-derived cardiomyocytes to 81 compounds and analyzed the spent media using UPLC-HRMS-based metabolomics. Cardiotoxicity potential was predicted based on changes in five metabolites and cell viability.
*Percent of Subclass Correctly Predicted as Cardiotoxic